Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit

Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug resistance occurs in a substantial number of patients. In resource-limited settings, genotypic resistance assay using a commercial kit is cos...

Full description

Saved in:
Bibliographic Details
Main Authors: Praparattanapan,J., Tragoolpua,Y., Wongtrakul,J., Kotarathitithum,W., Chaiwarith,R., Nuntachit,N., Sirisanthana,T., Supparatpinyo,K.
Format: Article
Published: IOS Press 2015
Subjects:
Online Access:http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84871581278&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38233
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-38233
record_format dspace
spelling th-cmuir.6653943832-382332015-06-16T07:46:41Z Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit Praparattanapan,J. Tragoolpua,Y. Wongtrakul,J. Kotarathitithum,W. Chaiwarith,R. Nuntachit,N. Sirisanthana,T. Supparatpinyo,K. Medicine (all) Biochemistry, Genetics and Molecular Biology (all) Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug resistance occurs in a substantial number of patients. In resource-limited settings, genotypic resistance assay using a commercial kit is costly. Objective: Focus on the validation of an in-house HIV-1 specific genotypic drug resistance assay in Thai patients failing cART. Materials and methods: Results of HIV-1 genotypic drug resistance assay was evaluated by comparing an inhouse method to a commercial test. The TRUGENE HIV-1 genotyping kit was used in 79 plasma specimens (49 from HIV patients failing cART therapy and 30 from proficiency testing panels). Results: The results from the in-house assay were comparable to those obtained from the TRUGENE HIV-1 genotyping kit with >99.0% codon-to-codon agreement. The lower limit of detection by the in-house assay was approximately 100 copies/mL of HIV-1 RNA. In addition, this in-house assay would allow testing of samples from patients infected with HIV-1 subtype other than B. Conclusion: The in-house HIV-1 genotypic drug resistance assay may be used as an alternative to commercial kits, particularly in resource limited settings. 2015-06-16T07:46:41Z 2015-06-16T07:46:41Z 2011-04-01 Article 19057415 2-s2.0-84871581278 10.5372/1905-7415.0502.032 http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84871581278&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38233 IOS Press
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine (all)
Biochemistry, Genetics and Molecular Biology (all)
spellingShingle Medicine (all)
Biochemistry, Genetics and Molecular Biology (all)
Praparattanapan,J.
Tragoolpua,Y.
Wongtrakul,J.
Kotarathitithum,W.
Chaiwarith,R.
Nuntachit,N.
Sirisanthana,T.
Supparatpinyo,K.
Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit
description Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug resistance occurs in a substantial number of patients. In resource-limited settings, genotypic resistance assay using a commercial kit is costly. Objective: Focus on the validation of an in-house HIV-1 specific genotypic drug resistance assay in Thai patients failing cART. Materials and methods: Results of HIV-1 genotypic drug resistance assay was evaluated by comparing an inhouse method to a commercial test. The TRUGENE HIV-1 genotyping kit was used in 79 plasma specimens (49 from HIV patients failing cART therapy and 30 from proficiency testing panels). Results: The results from the in-house assay were comparable to those obtained from the TRUGENE HIV-1 genotyping kit with >99.0% codon-to-codon agreement. The lower limit of detection by the in-house assay was approximately 100 copies/mL of HIV-1 RNA. In addition, this in-house assay would allow testing of samples from patients infected with HIV-1 subtype other than B. Conclusion: The in-house HIV-1 genotypic drug resistance assay may be used as an alternative to commercial kits, particularly in resource limited settings.
format Article
author Praparattanapan,J.
Tragoolpua,Y.
Wongtrakul,J.
Kotarathitithum,W.
Chaiwarith,R.
Nuntachit,N.
Sirisanthana,T.
Supparatpinyo,K.
author_facet Praparattanapan,J.
Tragoolpua,Y.
Wongtrakul,J.
Kotarathitithum,W.
Chaiwarith,R.
Nuntachit,N.
Sirisanthana,T.
Supparatpinyo,K.
author_sort Praparattanapan,J.
title Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit
title_short Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit
title_full Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit
title_fullStr Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit
title_full_unstemmed Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit
title_sort comparison of in-house hiv-1 genotypic drug resistant test with commercial hiv-1 genotypic test kit
publisher IOS Press
publishDate 2015
url http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84871581278&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38233
_version_ 1681421436368977920